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Risk factors and mortality of acute 
kidney injury within 1 month 
after lung transplantation
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Moo Suk Park1*
After lung transplantation (LT), some patients are at risk of acute kidney injury (AKI), which 
is associated with worse outcomes and increased mortality. Previous studies focused on AKI 
development from 72 h to 1 week within LT, and reported main risk factors for AKI such as 
intraoperative hypotension, need of ECMO support, ischemia time or longer time on waiting list. 
However, this period interval rarely reflects medical risk factors probably happen in longer post-
operative period. So, in this study we aimed to describe the incidence and risk factor of AKI within 
post-operative 1 month, which is longer follow up duration. Among 161 patients who underwent 
LT at Severance hospital in Seoul, Korea from October 2012 to September 2017, 148 patients were 
retrospectively enrolled. Multivariable logistic regression and Cox proportional hazard models were 
utilized. Among 148 patients, 59 (39.8%) developed AKI within 1-month after LT. Stage I or II, and 
stage III AKI were recorded in 26 (17.5%) and 33 (22.2%), respectively. We also classified AKI according 
to occurrence time, within 1 week as early AKI, from 1 week within 1 month was defined as late AKI. 
AKI III usually occurred within 7 days after transplantation (early vs. late AKI III, 72.5% vs 21.1%). Risk 
factor for AKI development was pre-operative anemia, higher units of red blood cells transfused during 
surgery, colistin intravenous infusion for treating multi drug resistant pathogens were independent 
risk factors for AKI development. Post-operative bleeding, grade 3 PGD within 72 h, and sepsis were 
more common complication in the AKI group. Patients with AKI III ([24/33] 72.7%) had significantly 
higher 1-year mortality than the no-AKI ([18/89] 20.2%), and AKI I or II group ([9/26] 34.6%), log-
rank test, P < 0.001). AKI was associated with worse post-operative outcome, 3-month, and 1-year 
mortality after LT. Severity of AKI was usually determined in early post op period (ex. within 7 days) 
after LT, so optimal post-operative management as well as recipients selection should be considered.
Lung transplantation (LT) has become the standard treatment for patients with terminal lung diseases, and over 
69,000 LTs have been performed worldwide from the early  90s1. The median survival of LT has improved recently 
to 6.7 years, compared to 5.6 years in the previous decade, as techniques and experiences with transplantation 
have  grown1,2.
Acute kidney injury (AKI) arises as a consequence of different pathological conditions, such as renal hypop-
erfusion, nephrotoxic exposure, sepsis, or major  surgery3. In LT, AKI is a common complication, shown to be 
associated with higher mortality and morbidity, primary graft dysfunction (PGD), and longer intensive care 
unit  stay4–6.
The incidence of post-operative AKI after LT has been described literature, ranging from 9.4 to 68.8%4–10. 
This wide range could be explained by the use of different AKI definitions, and recently, Ploypin et al. reported 
that the overall estimated incidence rate of AKI after LT is 52.5% via a systematic review adjusting for different 
AKI definitions such as the Risk, Injury, Failure, Loss of function; and End-stage kidney disease (RIFLE) criteria 
and the Acute Kidney Injury Network (AKIN)  criteria11.
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Another reason for the wide range of incidence rates could be the timing at which AKI is determined. Some 
studies have defined AKI as that within 72 h after LT, as a concept called early post-operative  AKI8, others have 
defined AKI as that occurring over a post-operative period of 3–14  days5,12,13.
In the present study, AKI was defined as that within 1 month after LT, longer than previous studies. We did 
this to include factors that have rarely been documented, but may pose greater susceptibility to AKI, such as 
infections with antimicrobial resistance species, and increasing exposure to nephrotoxic agents. We also com-
pared risk factors, post-operative outcomes, including 3-month and 1-year mortality, according to AKI severity 
and timing of AKI development.
Materials and methods
Study population and data collection. We retrospectively reviewed the medical records of 161 LT 
recipients’ treated at Severance Hospital, in Seoul, South Korea from October 2012 to September 2017. Patients 
were excluded if they were under the age of 18 years, underwent both lung and kidney transplantation, under-
went LT with off-pump coronary artery bypass, had already undergone renal replacement therapy(RRT), or had 
undergone re-transplantation. Thirteen patients were excluded (Fig. 1).
Data on variables related to baseline patient characteristics, pre-operative and post-operative outcomes, and 
survival status were obtained from the hospital medical records. Donor data were collected from the Korean 
Network of Organ Sharing database.
The primary outcome was the incidence of AKI within 1 month in patients that underwent LT. The AKIN 
definition was used to grade the severity of AKI. Secondary outcomes were days of mechanical ventilator usage, 
length of stay (LOS) in the intensive care unit (ICU), and 3-month and 1-year mortality.
The Institutional Review Board of Severance Hospital approved the study protocol in accordance with guide-
lines of the Declaration of Helsinki (IRB No: 4-2020-0228) and waived the need to obtain informed consent 
considering the retrospective nature of the study. All methods were carried out in accordance with relevant 
guidelines and regulations.
Immunosuppression protocol and post-operative fluid balance. All patients received intrave-
nous methylprednisolone (500 mg) intraoperatively just before the reperfusion of each graft. Post-operatively, 
Figure 1.  Study population and incidence of acute kidney injury of lung transplant recipients. 39.9% recipients 
developed acute kidney injury after lung transplantation within 1 month. *Early AKI, acute kidney injury within 
1 week; ¶late AKI, acute kidney injury after 1 week but within 1 month; RRT renal replacement therapy, LT lung 
transplantation, KT kidney transplantation, OPCAB off-pump coronary artery bypass, AKI acute kidney injury.
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patients received a 7-day tapered course of prednisolone, followed by oral prednisolone 0.5 mg/kg/day tapered 
to 0.15 mg/kg/day over 6 months. Triple immunosuppression therapy, such as prednisolone, tacrolimus, and 
mycophenolate mofetil, were used to maintain immunosuppression after transplantation. Cefepime and teico-
planin were used as routine prophylactic antibiotics after LT. Ganciclovir, itraconazole, and sulfamethoxazole/
trimethoprim were used as routine universal prophylactic therapy.
In the immediate post-operative period, most patients were titrated a daily average of 500 ml of negative fluid 
balance, based on the amount of body weight gain after surgery. Input and output control was slowly modulated 
in case of AKI or shock status using inotropics.
AKI definition. AKI was evaluated in accordance with AKIN classification. AKI stage I was defined as an 
increased serum creatinine (sCr) level ≥ 0.3 mg/dl (≥ 26.5 μmol/l) or an increase in sCr of 150–200% (1.5- to 2- 
fold) above baseline, along with a urine output of < 0.5 ml/kg/h for more than 6 h. AKI stage II was defined as an 
increase in sCr of 200% to 300% (> 2-to 3-fold) above baseline, with a urine output of < 0.5 ml/kg per hour for 
more than 12 h. AKI stage III was defined as an increase in sCr of more than 300% (> 3-fold) above baseline, or 
(sCr) level ≥ 4.0 mg/dl (≥ 35.4 μmol/l), with an acute increase of at least 0.5 mg/dl (44 μmol/l) or placement on 
RRT and urine output < 0.3 mg/kg/h for 24 h or anuria for 12  h14.
Baseline sCr levels were evaluated before LT. If AKI developed in a patient, we tracked the data daily until 
the self-remission of AKI. We obtained sCr levels immediately after LT up until 1 month after surgery. The 
modification of diet in renal disease equation was utilized to obtain the baseline estimated glomerular filtration 
rate (eGFR). Pulmonary hypertension was defined as the mean pulmonary artery pressure ≥ 25 mm Hg at rest, 
measured during right heart  catheterization15.
Early AKI was defined as AKI that developed within 1 week after LT. Late AKI was defined as AKI that 
developed after 1 week, but within 1 month, after LT.
According to previous literatures reported in Asian transplantation center, they commonly use AKI definition 
as AKIN, and MDRD equation. So we decided to use the same  modality13,16.
Post-operative complications. Primary graft dysfunction was graded according to the criteria of the 
International Society of Heart and Lung Transplant (ISHLT) Working Group. The proposed standardized defini-
tion of PGD was based on diffuse pulmonary edema in an allograft on a chest radiograph and a  PaO2/FiO2 (P/F) 
 ratio17.
Pneumonia was defined as the presence of infiltration on chest X-ray and positive sputum cultures on bron-
chioalveolar lavage cultures requiring antibiotic treatment within 1 month. Sepsis was defined as any positive 
blood culture within 1 month after LT, with evidence of organ  dysfunction18.
Operation time was defined as duration between induction time to end of skin suture time. Ischemia time was 
defined as the time interval between the application of the aortic cross-clamp during harvesting and reperfusion 
of the graft in the recipient.
Statistical analysis. Most data were analyzed using IBM SPSS Statistics for Windows, version 23 (IBM 
Corp., Armonk, N.Y., USA). Data are expressed as mean or median values with standard deviations or interquar-
tile ranges (IQRs). Continuous variables are presented as median (IQRs) were analyzed using the Mann–Whit-
ney U test. Categorical variables are displayed as frequency distributions (n) and simple percentages (%), and 
were analyzed using the chi-square test or Fisher’s exact test. Binary logistic regression analysis was performed to 
identify risk factors associated with AKI development within 1 month. Kaplan–Meier curves stratified according 
to AKI stage were constructed for the evaluation of mortality at 3-months and 1-year after LT. Factors associated 
with survival were adjusted for using Cox regression analysis. Multivariable Cox proportional hazards analy-
ses, including all variables with P less than 0.1 on univariate analysis, were performed to determine variables 
associated with long-term mortality. To assess the validity of the proportional hazards assumption, log-minus 
log-survival function, time-dependent covariate analysis was used. The time-dependent covariate was not sta-
tistically significant, suggesting that the proportional hazards assumption was reasonable. Estimates for hazard 
ratios (HR) and 95% confidence intervals (CIs) were reported. For all analyses, P values less than 0.05 were 
considered statistically significant.
Results
Characteristics and incidence of post-operative AKI. A total of 148 lung transplants recipients were 
analyzed. Among them, 59 patients (39.9%) developed AKI within 1 month; 89 patients (60.1%) maintained 
normal renal function. Twenty-six patients (17.5%) were classified with AKI stage I or II and 33 recipients 
(22.2%) were classified with AKI stage III. Among patients with AKI stage III, 88% (29/33) developed AKI 
within 1 week after LT during the early post-operative period. Meanwhile, the majority of patients with AKI 
stage I or II had increased sCr levels after 1 week and within 1 month after LT (Fig. 1).
There were no significant differences in demographic characteristics, such as age or sex, between the AKI and 
the no-AKI groups (Table 1). However, pre-operative comorbidities, including bridging mechanical ventilation 
(MV) and Extra corporeal membrane oxygenation (ECMO) for respiratory failure prior to surgery, were more 
severe in the AKI group. Pre-operative anemia and hypoalbuminemia was observed in the post-operative AKI 
group.
Intra-operative variables and donor characteristics. During LT, operation times were significantly 
longer in the AKI group than in the non-AKI group, and a higher number of packed red blood cell (RBC) units 
was transfused during surgery. Larger fluid intake and output was observed in the AKI group during surgery. 
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Table 1.  Baseline characteristics of 148 recipients according to acute kidney injury within 1 month after 
lung transplantation. Data are presented as numbers (%) or means ± standard deviation (SD). BMI body 
mass index, IPF idiopathic pulmonary fibrosis, CTD connective tissue disease, ILD interstitial lung disease, 
AIP acute interstitial pneumonia, BO after PBSCT bronchiolitis obliterans after peripheral blood stem 
cell transplantation, Egfr estimated glomerular filtration rate, Hb hemoglobin, Cr creatinine, ECMO extra 
corporeal membrane oxygenation, CPB cardiopulmonary bypass, MV mechanical ventilation, RBC red blood 
cell, APACHE acute physiology and chronic health evaluation. *Other group included bronchiectasis, cor 
pulmonale, lymphangioleiomyomatosis (LAM), chronic obstructive pulmonary disease (COPD), and steroid 
resistant bronchiolitis obliterans organizing pneumonia. a P value determined by t test or χ2 test.
No AKI group (n = 89) AKI group (n = 59) P  valuea
Age, years, mean ± SD 53.13 ± 11.50 55.24 ± 11.13 0.272
Male, sex, n (%) 55 (61.8) 34 (57.6) 0.610
BMI, kg/m2, mean ± SD 21.62 ± 3.88 21.30 ± 3.96 0.625
Primary lung disease, n (%) 0.307
IPF 55 (67.9) 26 (44.1)
CTD related ILD 11 (12.5) 10 (16.9)
AIP 1 (25.0) 3 (5.1)
BO after PBSCT 6 (6.8) 6 (10.2)
Other* 15 (17.1) 14 (23.8)
Comorbidities, n (%)
Hypertension 25 (28.1) 11 (18.6) 0.190
Diabetes mellitus 23 (25.8) 15 (25.4) 0.954
Pulmonary hypertension 43 (48.3) 30 (50.8) 0.763
Laboratory test, mean ± SD
Hb, g/day 12.19 ± 2.55 11.10 ± 2.25 0.009
Cr (baseline), mg/dL 0.57 ± 0.17 0.53 ± 0.23 0.170
eGFR (baseline) 88.8 ± 3.91 88.9 ± 3.92 0.879
Albumin, mg/day 3.17 ± 0.83 2.89 ± 0.74 0.043
Donor data
Donor age, years, mean ± SD 41.30 ± 12.00 42.2 ± 12.40 0.664
Donor sex, n (%) 55 (56.1) 32 (62.7) 0.149
Smoking, pack years, mean ± SD 6.52 ± 11.30 7.78 ± 10.90 0.501
Perioperative variables
Pre-op ECMO bridging, n (%) 10 (11.2) 14 (23.7) 0.044
Pre-op MV, n (%) 17 (19.1) 23 (39.0) 0.008
pre-op APACHE II score, mean ± SD 24.25 ± 6.60 25.42 ± 8.12 0.639
Intra-operative support, n (%) 0.453
CPB 3 (3.4) 3 (5.1)
ECMO 86 (96.6) 56 (94.9)
Lunt transplantation 0.599
Bilateral 81 (94.2) 54 (94.7)
Single 5 (5.8) 3 (5.3)
Ischemia time, h, mean ± SD 306.42 ± 89.44 311.90 ± 83.58 0.708
Operation time, h, mean ± SD 7.78 ± 1.29 8.55 ± 1.95 0.005
Donor-recipient size mismatch, n (%) 17 (19.1) 13 (22.0) 0.664
Number of RBC transfusion units, n, mean ± SD 6.30 ± 3.93 9.00 ± 5.50 0.002
Hemodynamic unstable event during surgery, n (%) 56 (69.1) 39 (73.6) 0.361
Intraoperative fluid intake, ml 6681.30 ± 351.8 8874.70 ± 548.7 0.001
Intraoperative fluid output, ml 1412.86 ± 141.39 1995.38 ± 228.05 0.033
Postoperative antibiotics, n (%)
Colistin intravenous infusion 13 (14.6) 28 (47.5)  < 0.001
Colistin inhalation 26 (29.2) 27 (45.8) 0.040
Amikacin intravenous infusion 12 (13.5) 11 (18.6) 0.396
Amphotericin B intravenous infusion 12 (13.5) 14 (23.7) 0.109
Renal replacement therapy, n (%) 0 (0) 21 (35.6) 0.001
3-month mortality 4 (4.5) 13 (22.0) 0.001
1-year mortality 18 (20.2) 33 (55.9) 0.001
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Ischemia time and size mismatch between the recipient and donor lungs were similar between the groups. There 
was no significant difference in hemodynamic instability (systolic blood pressure under 90 mmHg or vasopres-
sor use) during transplantation. Over 90% of the patients in the AKI and non-AKI groups underwent bilat-
eral lung transplantation. Most recipients received ECMO support for intraoperative circulatory support than 
cardio-pulmonary bypass (CPB), Donor variables, such as age, sex, and smoking pack years, were similar in the 
two groups.
Post-operative variables. In the post-operative period, treatment with intravenous colistin or by inhala-
tion was significantly higher in the AKI group. Use of other nephrotoxic agents such as amphotericin B and 
amikacin, were similar between the two groups. Among patients with AKI, 35.6% received renal replacement 
therapy due to kidney failure, which was significantly higher than that in the non-AKI group.
Univariable and multivariable analysis for AKI. Risk factors associated with AKI after LT are shown 
in Table 2. Univariate analysis revealed that pre-operative anemia, number of RBC transfusion units, usage of 
intravenous colistin or by inhalation, and bridging MV or ECMO were risk factors for AKI. After multivari-
able analysis, anemia, number of RBC transfusion units during surgery, and intravenous colistin infusion were 
Table 2.  Logistic regression of risk factors for AKI after lung transplantation. a P value determined by logistic 
regression model. BMI body mass index, IPF idiopathic pulmonary fibrosis, CTD connective tissue disease, 
ILD interstitial lung disease, AIP acute interstitial pneumonia, BO after PBSCT Bronchiolitis obliterans after 
peripheral blood stem cell transplantation, eGFR estimated glomerular filtration rate, Hb hemoglobin, Cr 
creatinine, ECMO extra corporeal membrane oxygenation, MV mechanical ventilation, RBC red blood cell, 
APACHE Acute Physiology and Chronic Health Evaluation.
Variables
Univariate Multivariable
OR (95% CI) P  valuea OR (95% CI) P  valuea
Age 1.01 (0.98–1.04) 0.27
Sex, male 1.19 (0.60–2.32) 0.61
BMI (kg/m2) 0.97 (0.89–1.06) 0.62
Primary lung disease
IPF 0.49 (0.25–0.95) 0.04 0.536 (0.245–1.171) 0.118
CTD related ILD 1.44 (0.57–3.66) 0.43
AIP 4.71 (0.48–46.45) 0.18
BO after PBSCT 1.57 (0.48–5.11) 0.46
Hypertension 0.58 (0.26–1.30) 0.19
Diabetes mellitus 0.97 (0.46–2.07) 0.95
Pulmonary hypertension 1.10 (0.57–2.13) 0.76
Pre-op APACHE II score 1.02 (0.94–1.12) 0.63
Laboratory findings
Hb (g/day) 0.83 (0.72–0.95) 0.01 0.836 (0.701–0.996) 0.045
Cr (baseline), mg/dL 0.30 (0.05–1.67) 0.17
eGFR 1.00 (0.92–1.09) 0.87
Albumin (mg/day) 0.64 (0.42–0.99) 0.21
Perioperative variables
Operation time 1.35 (1.08–1.70) 0.11
Unit number of RBC transfusion 1.13 (1.04–1.21) 0.001 1.109 (1.018–1.208) 0.018
ECMO bridging 2.46 (1.0–5.9) 0.04 0.879 (0.246 -3.139) 0.879
Pre-op MV 2.7 (1.28–5.69) 0.009 1.544 (0.478–4.987) 0.468
Ischemia time 1.00 (0.99–1.00) 0.72
Size mismatch 1.20 (0.53–2.69) 0.66
Intra op CPB 1.53 (0.29–7.88) 0.60
Hemodynamic instablity 1.24 (0.57–2.69) 0.58
Post-operative variables
Colistin intraveous infusion 5.28 (2.42–11.51) 0.001 4.346 (1.695–11.144) 0.002
Colistin inhalation 2.04 (1.03–4.06) 0.04 0.679 (0.265–1.736) 0.679
Amikacin intravenous-infusion 1.47 (0.60–3.59) 0.39
Amphotericin B intravenous-infusion 1.20 (0.85—4.69) 0.11
Donor age 1.00 (0.97–1.03) 0.66
Donor sex 1.00 (0.55–2.11) 0.80
Donor smoking 1.00 (0.98–1.0) 0.49
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independent risk factors for AKI. Application of bridging ECMO or MV before LT was not associated with 
post-operative AKI.
Association between AKI and other post-operative complications. We compared the occurrence 
of other post-operative complications between AKI and the no-AKI group. Post-operative bleeding, grade 3 
PGD, and sepsis developed more commonly in the AKI group. AKI was associated with longer length of stay in 
the ICU and prolonged ventilator support during weaning (Table 3).
Stratified by AKI stage, grade 3 PGD and sepsis occurred more commonly in patients with AKI stage III. 
Also, prolonged ventilator support was more common in the AKI III group (Table 4).
Subgroup analysis of AKI characteristics according to the AKI severity and onset. There were 
no significant differences in baseline characteristics, comorbidities, or intraoperative variables between AKI 
stage I or II and AKI stage III. Risk factors for the development of AKI, such as anemia, number of RBC transfu-
sion units during surgery, and usage of intravenous colistin infusion, were not significantly different between the 
two severity groups (Supple Table 1). Also, there were no significant changes in body weight during the post-
operative period, indicating that similar management of fluid balance was applied.
We further evaluated AKI according to the timing of AKI occurrence. Early AKI was defined as that within 
1 week after LT, late AKI development was classified as that from 1 week to 1 month after LT (Supple Table 2). The 
incidence of early AKI was 67.7% (n = 40), while that for late AKI was 32.2% (n = 19). The reason for limiting late 
AKI to just 1-month was because, after one month, the incidence of AKI decreased to 7.4%, and after 1 month, 
there were no cases of HD or RRT (Supple Table 3). There were no significant differences in age, primary lung 
diseases, comorbidities, and bridging MV or ECMO between the two AKI timing groups. Also, there were no 
differences in intra-operative variables, such as intra-operative bleeding, intra-operative fluid intake, and RBC 
transfusion during surgery between the two groups. Interestingly, development of AKI stage III was more com-
mon in the early post-operative period (72.5% vs 21.1%) (Supple Table 2). AKI I or II tended to developed in late 
post-operative period (78.9% vs. 27.5%). However, Colistin usage, which was a risk factor for AKI development, 
was similar and reached over 40% in both groups. Overall, body-weight during surgery increased nearly 6.0 kg 
in the AKI group, and, slowly decreased to near pre-op body -weight within 2 weeks. However, in the early AKI 
group, the mean body-weight change between POD7 and POD3 was statistically lower than that in the late AKI 
group. (early AKI vs. late AKI; − 2.65[− 4.55, − 0.50] vs. − 3.70 [− 7.10, − 2.90]; P = 0.026] (Supple Table 2). In 
the early AKI group, the proportion of patients who received RRT due to renal failure was higher than that in 
the late AKI group (65.0% vs 21.1%, P = 0.002) (Supple Table 2).
AKI and mortality rates after lung transplantation. In Kaplan–Meier curves, the post-operative 
3-month mortality rate in patients with no AKI, AKI I or II, and AKI III were 4.5% (4/89), 3.8% (1/26), and 
Table 3.  Postoperative complications among lung transplant recipients according to AKI. Data are presented 
as number (%) or medians (interquartile ranges). GI bleeding gastrointestinal bleeding, PGD primary graft 
dysfunction, ICU intensive care unit, MV mechanical ventilation. a P value determined by t test or χ2 test.
No AKI group (n = 89) AKI group (n = 59) P  valuea
Postoperative bleeding, n (%) 4 (4.5) 17 (28.8) 0.001
GI bleeding, n (%) 8 (9.0) 7 (11.9) 0.381
Grade 3 PGD, 72 h, n (%) 8 (9.0) 16 (27.1) 0.004
Sepsis, n (%) 15 (16.9) 22 (37.3) 0.005
Pneumonia, n (%) 10 (38.5) 19 (57.6) 0.116
ICU stay, day (IQR) 7.00 (5.00–12.00) 14.00 (6.00–28.00) 0.004
MV day, day (IQR) 5.00 (4.00–10.00) 14.00 (6.00–26.50) 0.001
Table 4.  Postoperative complications among lung transplant recipients according to AKI severity. Data are 
presented as number (%) or medians (interquartile ranges). GI bleeding gastrointestinal bleeding, PGD primary 
graft dysfunction, ICU intensive care unit, MV mechanical ventilation. a P value determined by t test or χ2 test.
AKI stage I or II (n = 26) AKI stage III (n = 33) P  valuea
Postoperative bleeding, n (%) 5 (19.2) 12 (36.4) 0.124
GI bleeding, n (%) 2 (7.7) 5 (15.2) 0.323
Grade 3 PGD, 72 h, n (%) 3 (11.5) 13 (39.4) 0.016
Sepsis, n (%) 3 (11.5) 19 (57.6) 0.001
Pneumonia, n (%) 5 (19.2) 12 (36.4) 0.124
ICU Stay, day, median (IQR) 8.0 (5.0–28.0) 18.0 (6.0–30.0) 0.180
MV day, day, median (IQR) 9.5 (4.0–20.0) 18.0 (11.0–31.0) 0.003
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Figure 2.  Kaplan–Meier survival analysis of lung transplant recipients stratified by AKI stage: 3-month 
mortality A, and 1-year mortality B. (A) Kaplan–Meier 3-month mortality of lung transplant patients stratified 
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36.4% (12/33), respectively (log-rank test, P < 0.001, Fig. 2A). Patients with no AKI, and those with AKI I or II 
had no significant difference in 3-month mortality. However, the AKI stage III group had significantly higher 
mortality.
The 1-year mortality rates in patients with no AKI, AKI I or II, and AKI III were 20.2% (18/89), 34.6% (9/26), 
and 72.7% (24/33), respectively (log-rank test, P < 0.001, Fig. 2B). The more severe AKI became, the higher the 
1-year morality rate was. We further compared mortality in the AKI III group according to RRT use, and there 
was no significant difference in mortality between those who did or did not receive RRT (Supple Table 4). In the 
univariate Cox proportional model used for analyzing 1-year mortality, age, albumin, number of RBC transfusion 
units, and sepsis were risk factors for mortality after LT. In multivariable analysis, age and AKI were independent 
risk factors for 1-year mortality (Table 5).
Discussion
In our study, we focused on the development of AKI within 1 month, a longer follow-up duration than those in 
previous studies, which primarily focused on AKI at post-operative 72 h or 1  week4–10,19. Reflecting the natural 
course of kidney injury after LT, AKI more often appears to be an epiphenomenon of the pre-, intra-, and post-
operative clinical course after LT. A longer duration of follow up would be necessary to analyze post-operative 
factors, such as using nephrotoxic agents, sepsis, and other post-operative complications that affect AKI.
The incidence of AKI within 1 month after LT defined by AKIN classification was 39% in our cohort, lower 
than that reported in other studies. This could be explained by the older age and different proportions of primary 
lung disease compared to other studies. Serum creatinine is usually underestimated in older adult patients due 
to reduced muscle  mass20, and thus, changes in sCr levels could have been underestimated in our cohort. In the 
ISHLT registry report chronic obstructive pulmonary disease (COPD) was the most common indication in the 
last decade, while idiopathic interstitial pneumonia was the  second21. However, in our cohort the proportions of 
IPF and connective-tissue disease related interstitial lung disease were over 60%, while that of COPD was lower 
than 10%. These differences may explain the lower incidence of AKI development, compared to other studies.
Prior studies have reported on the risk factors of AKI after LT. Ishikawa et al. reported that perioperative risk 
factors of AKI within 72 h included intraoperative hypoxemia  (SpO2 < 90%) in patients that underwent double-
lung transplantation, compared to those that underwent single-lung  transplantation8. Balci et al. reported on 
perioperative risk factors of LT within 1 month as intraoperative hypotension and systemic infection in the 
post-operative  period9. Amphotericin B use and high tacrolimus level were reported as risk factors of AKI in 
some  studies10,22.
The main finding of our study is that pre-operative anemia, number of RBC units transfused during surgery, 
and usage of colistin intravenous for multi drug resistant (MDR) pathogens independently are correlated with 
AKI development. Ho et al. reported that in cases of cardiac surgery with cardiopulmonary bypass, nearly all 
patients are at the ‘initiation phase’ of ischemia–reperfusion kidney injury with proximal tubular dysfunction. 
They suggested that the ‘extension phase’ of kidney injury is related with the severity of inflammatory response, 
renal hypoxia, and oxidative  stress23,24. As CPB, and ECMO are used during LT, similar principals would likely 
apply. Accordingly, one could be reason that those described risk factors would be variables preventing recovery 
from initial kidney injury, therby leading to, progressing to AKI.
Underlying anemia has been shown to be associated with prolonged hypoxemia and could result in AKI in 
the post LT  period25. Recipients of LT already face respiratory failure due to primary lung disease, which could 
be further aggravated by anemia, inducing a prolonged hypoxemic status. This reduced oxygen-carrying capacity 
Table 5.  Cox proportional hazard regression model for 1-year mortality after lung transplantation. BMI body 
mass index, Hb hemoglobin, ECMO extra corporeal membrane oxygenation, MV mechanical ventilation, 




HR (95% CI) P  valuea HR (95% CI) P  valuea
Age, years 1.097 (1.058–1.137) 0.001 1.092 (1.051–1.135) 0.001
BMI, kg/m2 1.050 (0.981–1.124) 0.162
Hb 0.902 (0.796–1.021) 0.102
Albumin 0.656 (0.455–0.946) 0.024 0.850 (0.559–1.293) 0.447
Pre-op ECMO 1.085 (0.484–2.433) 0.844
Pre-op MV 1.501 (0.796–2.832) 0.210
Number of RBC transfusion units 1.067 (1.014–1.123) 0.012 1.030 (0.965–1.099) 0.369
Operation time 4.71 (0.48–46.45) 0.180
Colistin intravenous infusion 1.640 (0.879–3.060) 0.120
AKI 3.688 (1.992–6.829) 0.001 2.921 (1.495–5.707) 0.002
PGD 3, 72 h 1.719 (0.826–3.578) 0.148
Sepsis, within 1 month 2.133 (1.143–3.983) 0.017 1.473 (0.725–2.990) 0.284
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elicits sympathetic nerve system increases in vascular resistance, causing vasoconstriction and leading to renal 
hypo-perfusion26. Thus, anemia prior to surgery risk for developing AKI in LT recipients.
An increased amount of packed RBC transfusion units can induce transfusion-related adverse effects. Intra-
operative RBC requirements are most likely necessary due to intraoperative requirements for hemodynamics, 
although in our analysis, observed hemodynamic instability during surgery was not statically related to AKI 
development, despite RBC requirements being statistically higher in the AKI group. Garg et al. reported in a 
randomized controlled trial, that restrictive transfusion of RBC was not inferior as an outcome of post-operative 
AKI in cardiac surgery with  CPB24,27. A unit of RBC is known to be stored up to 42 days and can undergo 
erythrocyte membrane change, becoming more fragile and leading to progressive hemolysis. Accumulation of 
pro-inflammatory molecules, free hemoglobin, and iron can lead to the development of  AKI28.
Among nephrotoxic antibiotics, Intravenous colistin which was used to treat MDR pathogens, was an inde-
pendent risk factor for developing AKI. Colistin has high intrinsic renal toxicity and accumulates within the 
proximal cortical tissue. Combined with anemia, age, liver disease, and baseline GFR, colistin has been reported 
as a risk factor for  AKI29. Thus, these findings support that LT recipients who already have anemia are prone to 
AKI after colistin use. In Southeast Asia, an increased incidence of MDR infections among ICU patients has been 
 reported30. A similar situation was observed in our study. A total of 54% (n = 80) of the recipients experienced 
infections with MDR pathogens. The proportions of Acinetobacter, Pseudomonas, and Klebsiella were 30.4% 
(n = 45), 15.1% (n = 22), and 18.9% (n = 28), respectively.
In patients who developed AKI, post-operative complications of post-operative bleeding, grade 3 PGD, and 
sepsis occurrence were more common, compared to those without AKI. The cause and effect of AKI, as well as 
the complications, were unclear because patients with these complications could develop AKI both early and 
Figure 3.  A visual summary in this study. Incidence, risk factors and mortality of acute kidney injury after lung 
transplantation. During waiting period, LT candidates have end-stage lung disease (gray lung) with normal renal 
function (brown kidney). Through clinical course of a pre-, intra-, and post-operative process, AKI more often 
to be appeared with risk factor such as anemia, RBC transfusion and intravenous colistin. Although recipients 
have a successful new transplanted lung (pink lung), AKI group (dark brown kidney) has higher 1-year 
mortality with more common complications such as post-operative bleeding, grade 3 PGD, sepsis. As the stage 
of AKI become severe, the mortality gets higher. Especially AKI with stage III have the highest 1-year mortality, 
up to 72.7%. We underwent LT to prolong life expectancy of terminal lung disease patients, however recipients 
with AKI become poorly survive within 1-year, unfortunately. Figure 3 was drawn by MID (Medical Illustration 
& Design), part of the Medical Research Support Services of Yonsei University College of Medicine. AKI acute 
kidney injury, RBC red blood cells, Hb hemoglobin, IV intravenous, PGD primary graft dysfunction.
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later after LT. However, in our study, it was clear that sepsis and grade 3 PGD were strongly associated with severe 
AKI, the majority of cases of which occurred within 7 post-operative days, resulting in increased mortality.
In this study, poor respiratory outcomes (prolonged ventilator days and longer ICU stay) were more com-
mon in the AKI group. The renal tubular epithelium is a major site of cell injury and death in AKI, where 
cytokines, oxidative stress, and leukocytes initiate local and systemic inflammation. The lungs, with their large 
capillary networks, are capable of sequestering a large number of inflammatory/immune  cells31. Moreover, AKI-
induced derangement of nitric oxide synthase and heme oxygenase (key oxidative stress enzymes) may influence 
lung  function32. This could lead to post-LT respiratory failure, leading to difficulty in weaning a patient off the 
ventilator.
Post-operative treatment of transplanted sick patients can be difficult and challenging. In our study, recipients 
who develop of AKI experience poor post-operative outcomes and mortality. Post-operative AKI could be a 
marker indicating that LT recipients are not going to do well. Pre-operative anemia, number of RBC transfused 
units during surgery, and usage of intravenous colistin were independent predictors of the development of AKI.
Managing the difficult course involving AKI could be important in post-operative care of transplanted sick 
patients. Technical bleeding control and not having an excessive packed RBC transfusion would be considered in 
individuals susceptible to AKI. Also, in instances where an infection with MDR pathogens is documented within 
7 days, waiting to determine whether it is a true infection or contamination may be advisable, and using colistin 
inhalation rather than colistin infusion could be another option for post op management. Also, if the candidates 
were in vulnerable for developing many complications such as AKI selection of recipients for lung transplantation 
would be a better management strategy, considering organ scarcity and predicted survival outcome.
Our study had several limitations. It was single-center, retrospective cohort study, thus generalizability of 
our findings may be limited. Second, dosage and duration of administered nephrotoxic agents were not fully 
evaluated due to inadequate information.
Conclusion
In post lung transplantation, AKI was developed 39% within one month. The main risk factors for AKI was 
anemia, higher number of RBC transfusion units during surgery, and intravenous colistin infusion (Fig. 3). AKI 
was associated with worse post-operative outcome and 3-month, 1-year mortality after LT. Severity of AKI was 
usually determined in early post op period after LT, so optimal post-operative management as well as recipients 
selection should be done in sick candidates with highly susceptible to become AKI.
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